While LOX-PP was described as a Ras tumor suppressor, reversing mesenchymal tumor cells to a more epithelial phenotype [76–78], the LOX enzyme was found to facilitate a more migratory and invasive phenotype during breast cancer progression [58, 79]. This evidence concerns the gene LOX and breast carcinoma.